Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ)
Your view on XVIPY
Overview
What the company does, where it operates, and who runs it.
About Xvivo Perfusion AB (publ)
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Christoffer Rosenblad
- Headquarters
- MAessans gata 10, Gothenburg, SE
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Christoffer Rosenblad
- Headquarters
- MAessans gata 10, Gothenburg, SE
Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific.
The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP.
It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP.
In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product.
The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Xvivo Perfusion AB (publ), and the rating behind it. XVIPY last traded at $6.54, 89.1× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Xvivo Perfusion AB (publ). Starting points for Xvivo Perfusion AB (publ): P/E 89.1, EPS $0.70, beta 1.89 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Xvivo Perfusion AB (publ). Xvivo Perfusion AB (publ) does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Xvivo Perfusion AB (publ). Trailing twelve-month EPS for Xvivo Perfusion AB (publ) stands at $0.70. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Xvivo Perfusion AB (publ). Xvivo Perfusion AB (publ) has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Xvivo Perfusion AB (publ) valued side by side against its closest peers. Xvivo Perfusion AB (publ) is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Xvivo Perfusion AB (publ), and how their positions are changing. At a $824.0M market value, institutional positions materially move Xvivo Perfusion AB (publ)'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Xvivo Perfusion AB (publ) executives and directors. Shares of Xvivo Perfusion AB (publ) have traded between $4.25 and $8.74 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Xvivo Perfusion AB (publ). Xvivo Perfusion AB (publ) is a $824.0M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Xvivo Perfusion AB (publ). Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Xvivo Perfusion AB (publ). Coverage tracks Xvivo Perfusion AB (publ) within Medical - Devices (Healthcare). Press releases and market coverage, newest first.